492 related articles for article (PubMed ID: 15176996)
21. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1).
Kwak HB; Jin HM; Ha H; Kang MJ; Lee SB; Kim HH; Lee ZH
Biochem Biophys Res Commun; 2005 May; 330(4):1080-6. PubMed ID: 15823554
[TBL] [Abstract][Full Text] [Related]
22. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis.
Kanazawa K; Azuma Y; Nakano H; Kudo A
J Bone Miner Res; 2003 Mar; 18(3):443-50. PubMed ID: 12619928
[TBL] [Abstract][Full Text] [Related]
23. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
24. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
25. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL).
Matsumoto M; Sudo T; Saito T; Osada H; Tsujimoto M
J Biol Chem; 2000 Oct; 275(40):31155-61. PubMed ID: 10859303
[TBL] [Abstract][Full Text] [Related]
26. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
27. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
Voronov I; Heersche JN; Casper RF; Tenenbaum HC; Manolson MF
Biochem Pharmacol; 2005 Jul; 70(2):300-7. PubMed ID: 15919055
[TBL] [Abstract][Full Text] [Related]
30. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
31. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
32. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
34. Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.
Takuma A; Kaneda T; Sato T; Ninomiya S; Kumegawa M; Hakeda Y
J Biol Chem; 2003 Nov; 278(45):44667-74. PubMed ID: 12944401
[TBL] [Abstract][Full Text] [Related]
35. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.
Lam J; Takeshita S; Barker JE; Kanagawa O; Ross FP; Teitelbaum SL
J Clin Invest; 2000 Dec; 106(12):1481-8. PubMed ID: 11120755
[TBL] [Abstract][Full Text] [Related]
36. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
Sugatani T; Alvarez UM; Hruska KA
J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
38. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
[TBL] [Abstract][Full Text] [Related]
39. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA
Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
[TBL] [Abstract][Full Text] [Related]
40. Self-assembled RANK induces osteoclastogenesis ligand-independently.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 Nov; 20(11):2053-60. PubMed ID: 16234979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
